Urology News and Research

Latest Urology News and Research

Cincinnati Children's provides tips on how to stop the spread of flu germs

Doctors at Cincinnati Children's Hospital Medical Center want to make sure children are protected from influenza this flu season. The flu is an infection of the nose, throat and lungs caused by a variety of strains of influenza viruses.

18 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

Rochester Medical enters agreement with Fornix to acquire Laprolan

Rochester Medical Corporation today announced it had reached an agreement with Fornix N.V. to purchase from Fornix its wholly owned subsidiary Laprolan B.V., a medical supplies distribution company located in Beuningen, The Netherlands.

12 Jan 2011

RAS includes Merge iConnect solution

Merge Healthcare, a leading health IT solutions provider, today announced that Radiology Associates of Sacramento (RAS), the largest private radiology practice in Northern California, has expanded their Merge solution suite to include Merge iConnect.

12 Jan 2011

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

BPH, hair loss prevention drugs may produce adverse side effects in men

Researchers from Boston University School of Medicine, in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors, while improving urinary symptoms in patients with benign prostatic hyperplasia and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction, ejaculatory dysfunction and potential depression.

12 Jan 2011

Watson receives FDA approval for generic Fentora

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Fentanyl Buccal tablets, USP, in the 0.1, 0.2, 0.4, 0.6 and 0.8 mg strengths, the generic equivalent to Cephalon's Fentora ® tablets.

10 Jan 2011

Endo Pharmaceuticals receives FDA complete response letter for OPANA ER

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration regarding the New Drug Application for its new formulation of OPANA® ER designed to be crush resistant.

10 Jan 2011

World's largest medical robotic conference

The International Robotic Urology Symposium 2011 is hosted by the Henry Ford Vattikuti Urology Institute and the Vattikuti Foundation.

7 Jan 2011

Pros and cons of weight loss surgery in men and women

Women who underwent gastric band surgery to lose weight reported significant improvements in urinary function and quality of life after the operation, according to research published in the January issue of the urology journal BJUI.

6 Jan 2011

Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors

A select 40 physician-researchers at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center were named 2011 Southern California Super Doctors in the January issue of Los Angeles Magazine.

4 Jan 2011

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

FDA approves Watson's novel oral contraceptive

Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.

22 Dec 2010

Molecular breakdown of Bicoid protein vital for normal patterning of fruit fly's offspring

Using fruit flies as a model to study embryo formation, scientists report in Nature Cell Biology that molecular breakdown of a protein called Bicoid is vital to normal head-to-tail patterning of the insect's offspring.

22 Dec 2010

Tips on toy safety during holiday season

With the excitement of the holidays, parents and relatives eagerly purchase the hottest toys and latest items for their children. But it's during the hustle and bustle of the season that many fail to buy age appropriate gifts for their children, and they tend to disregard warnings on these toys and gifts to ensure they are safe.

22 Dec 2010

Men above age 75 with high-risk prostate cancer often under-treated

Older men with high-risk prostate cancer frequently are offered fewer - and less effective - choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.

22 Dec 2010

AHA recognizes UC Irvine Medical Center's commitment to high-quality cardiac care

The American Heart Association has recognized UC Irvine Healthcare's commitment to the highest standards of care for heart failure patients.

17 Dec 2010

New study suggests PSA test effective for men with prostate cancer

The PSA screening test for prostate cancer is not perfect. It can indicate cancer when none is present and miss life-threatening tumors. But a new study suggests the test is more reliable in men taking dutasteride (Avodart®), a drug widely prescribed to shrink an enlarged prostate gland.

17 Dec 2010

UT Southwestern and Rabin Medical Center enter innovative 5-year affiliation agreement

UT Southwestern Medical Center and Rabin Medical Center, Israel, two of the world's top academic medical centers, announced today that they have entered into an innovative affiliation agreement for the next five years.

16 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010